L19IL2/TNF in Patients With Basal Cell Carcinoma

Inclusion Criteria: * Patients must have histologically documented, locally advanced BCC. * Patients must have at least one injectable and measurable cutaneous or subcutaneous lesion. * Patients must have locally advanced BCC that has progressed on or cannot tolerate ICI treatment as assessed by a local multidisciplinary tumor board. * Patients with nodal, regional or in transit injectable BCC lesions. * Patients must be willing to provide tissue from a core or excisional biopsy of a tumor lesion at screening and for confirmation of Objective Response or Stable Disease. * Male or female patients, age 18 - 100 years. * ECOG Performance Status/WHO Performance Status ≤ 2. * Hemoglobin \> 10.0 g/dL. * Platelets \> 100 x 109/L. * ALT and AST, GGT and Lipase ≤ 1.5 x the upper limit of normal (ULN). * Chronically impaired renal function as indicated by creatinine clearance \< 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance \< 45 mL/min/1.73m2. * All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified. * Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to three months following the last study drug administration, highly effective contraception methods, as defined by the "Recommend…